Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$128,600.00
Towards Single-Step manufacturing of LNP Gene Therapy
FY 2018-19 · 2018-10-01
Summary
The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to incorporate our fusogenic proteins into lipid nanoparticles using the Precision Nanosystems microfluidic platform. We expect that by pre-formulating one of the lipid components with fusogenic protein, we may be able to reduce the manufacturing to a single step compared to the current 2 step process. This will allow us to significantly improve our encapsulation efficiency and simplify our manufacturing process as we move to the clinic.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2018-10-01 | 2018-19 | $117,600.00 |
| 2 | 2018-10-01 | 2018-19 | $128,600.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 11,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 11 000 dollars.
Agreement End Date
2019-09-30
Agreement Number
913718
Agreement Start Date
2018-10-01
Agreement Title
Towards Single-Step manufacturing of LNP Gene Therapy
Agreement Title (French)
Vers la fabrication en une étape de la thérapie génique LNP
Agreement Type
Contribution
Agreement Value
$128,600.00
Amendment Date
2019-02-25
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to incorporate our fusogenic proteins into lipid nanoparticles using the Precision Nanosystems microfluidic platform. We expect that by pre-formulating one of the lipid components with fusogenic protein, we may be able to reduce the manufacturing to a single step compared to the current 2 step process. This will allow us to significantly improve our encapsulation efficiency and simplify our manufacturing process as we move to the clinic.
Description (French)
L’objectif de ce projet est d’établir une méthode de synthèse des nanoparticules lipidiques d’ADN de Fusogenix à l’aide d’un processus de fabrication en une étape. Pour ce faire, nous évaluerons un certain nombre de méthodes pour incorporer nos protéines fusogènes dans des nanoparticules lipidiques à l'aide de la plate-forme microfluidique Precision Nanosystems. Nous nous attendons à ce que la pré-formulation de l’un des composants lipidiques avec la protéine fusogène nous permette de réduire la fabrication à une seule étape par rapport au processus actuel en deux étapes. Cela nous permettra d’améliorer considérablement notre efficacité d’encapsulation et de simplifier notre processus de fabrication lorsque nous irons à la clinique.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2018-2019-Q3-913718
